Novel Sulfonamide-Based Analogs of Metformin Exert Promising Anti-Coagulant Effects without Compromising Glucose-Lowering Activity
Open Access
- 21 October 2020
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (10), 323
- https://doi.org/10.3390/ph13100323
Abstract
Metformin, one of the most frequently prescribed oral anti-diabetic drugs, is characterized by multidirectional activity, including lipid lowering, cardio-protective and anti-inflammatory properties. This study presents synthesis and stability studies of 10 novel sulfonamide-based derivatives of metformin with alkyl substituents in the aromatic ring. The potential of the synthesized compounds as glucose-lowering agents and their effects on selected parameters of plasma and vascular hemostasis were examined. Compounds with two or three methyl groups in the aromatic ring (6, 7, 9, 10) significantly increased glucose uptake in human umbilical vein endothelial cells (HUVECs), e.g., 15.8 µmol/L for comp. 6 at 0.3 µmol/mL versus 11.4 ± 0.7 µmol/L for control. Basic coagulation studies showed that all examined compounds inhibit intrinsic coagulation pathway and the process of fibrin polymerization stronger than the parent drug, metformin, which give evidence of their greater anti-coagulant properties. Importantly, synthesized compounds decrease the activity of factor X, a first member of common coagulation pathway, while metformin does not affect coagulation factor X (FX) activity. A multiparametric clot formation and lysis test (CL-test) revealed that the examined compounds significantly prolong the onset of clot formation; however, they do not affect the overall potential of clot formation and fibrinolysis. Erythrotoxicity studies confirmed that none of the synthesized compounds exert an adverse effect on erythrocyte integrity, do not contribute to the massive hemolysis and do not interact strongly with the erythrocyte membrane. In summary, chemical modification of metformin scaffold into benzenesulfonamides containing alkyl substituents leads to the formation of potential dual-action agents with comparable glucose-lowering properties and stronger anti-coagulant activity than the parent drug, metformin.Funding Information
- Narodowe Centrum Nauki (2016/21/D/NZ7/01548)
- Uniwersytet Medyczny w Lodzi (503/3-015-01/503-31-001-19-00)
- Academy of Finland (294227)
This publication has 52 references indexed in Scilit:
- Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic ReviewPLOS ONE, 2013
- Shifting from the single to the multitarget paradigm in drug discoveryDrug Discovery Today, 2013
- Metformin Reduces Endogenous Reactive Oxygen Species and Associated DNA DamageCancer Prevention Research, 2012
- Effect of metformin on the proliferation, migration, and MMP-2 and -9 expression of human umbilical vein endothelial cellsMolecular Medicine Reports, 2012
- Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implicationsReviews in Endocrine and Metabolic Disorders, 2010
- 2′,7′-Dichlorodihydrofluorescein as a fluorescent probe for reactive oxygen species measurement: Forty years of application and controversyFree Radical Research, 2010
- Alterações do sistema hemostático nos pacientes com diabetes melito tipo 2RBGO Gynecology & Obstetrics, 2010
- A multiparameter test of clot formation and fibrinolysis for in-vitro drug screeningBlood Coagulation & Fibrinolysis, 2007
- Hyperglycemia Stimulates Coagulation, Whereas Hyperinsulinemia Impairs Fibrinolysis in Healthy HumansDiabetes, 2006
- A Simple and Rapid Laboratory Method for Determination of Haemostasis Potential in Plasma: II. Modifications for Use in Routine Laboratories and Research WorkThrombosis Research, 2001